Fig. 6: Effect of elacestrant in combination with targeted therapies.

A Effect of escalating doses of palbociclib or abemaciclib with or without elacestrant in MCF7 (0.5 nM), MCF7-LTED^wt (20 nM) and MCF7-LTED^Y537C (1.5 nM) indicated by the bar in each graph. B Effect of escalating doses of elacestrant, with or without everolimus (5 nM) or pictilisib (100 nM) in MCF7-LTED^Y537C. C Effect of escalating doses of elacestrant in MCF7-LTED^PalboR. Data represented are mean ± SEM (n = 3 biological experiments with six technical replicates).